CRMD CorMedix Inc
Price (delayed)
$7.21
Market cap
$402.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$374.8M
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its
Highlights
The gross profit has grown by 36% from the previous quarter
The company's debt fell by 19% YoY and by 6% QoQ
The gross margin has shrunk by 168% YoY
CorMedix's net income has decreased by 44% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of CRMD
Market
Valuations
Earnings
Shares outstanding
55.86M
Market cap
$402.75M
Enterprise value
$374.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.58
Price to sales (P/S)
515.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
464.95
Revenue
$806,119
EBIT
-$54.47M
EBITDA
-$54.34M
Free cash flow
-$51.2M
Per share
Balance sheet
Liquidity
EPS
-$0.93
Free cash flow per share
-$0.89
Book value per share
$0.84
Revenue per share
$0.01
TBVPS
$0.97
Total assets
$57.73M
Total liabilities
$11.55M
Debt
$594,323
Equity
$46.18M
Working capital
$42.08M
Debt to equity
0.01
Current ratio
4.79
Quick ratio
4.12
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-6,740.9%
Gross margin
-64.8%
Net margin
-6,589.1%
Operating margin
-7,212.5%
Return on assets
-71%
Return on equity
-82.5%
Return on invested capital
-224%
Return on capital employed
-116.9%
Return on sales
-6,757.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRMD stock price
How has the CorMedix stock price performed over time
Intraday
0%
1 week
4.34%
1 month
49.9%
1 year
92.27%
YTD
91.76%
QTD
66.51%
Financial performance
How have CorMedix's revenue and profit performed over time
Revenue
$806,119
Gross profit
-$522,259
Operating income
-$58.14M
Net income
-$53.12M
Gross margin
-64.8%
Net margin
-6,589.1%
The gross margin has shrunk by 168% YoY
CorMedix's operating margin has surged by 93% YoY
The company's net margin has surged by 93% YoY
The company's operating income has shrunk by 52% YoY and by 6% QoQ
Growth
What is CorMedix's growth rate over time
Valuation
What is CorMedix stock price valuation
P/E
N/A
P/B
8.58
P/S
515.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
464.95
The EPS has declined by 8% year-on-year
The P/B is 138% above the last 4 quarters average of 3.6 and 104% above the 5-year quarterly average of 4.2
CorMedix's equity has decreased by 20% QoQ and by 6% YoY
The price to sales (P/S) is 70% lower than the 5-year quarterly average of 1730.7
Efficiency
How efficient is CorMedix business performance
The return on sales has surged by 93% year-on-year
The company's return on invested capital fell by 34% YoY and by 21% QoQ
CorMedix's ROE has decreased by 20% YoY and by 7% from the previous quarter
The ROA has contracted by 16% YoY and by 5% from the previous quarter
Dividends
What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRMD.
Financial health
How did CorMedix financials performed over time
CorMedix's total liabilities has increased by 45% YoY and by 15% QoQ
The quick ratio fell by 42% YoY and by 33% QoQ
The company's debt is 99% lower than its equity
CorMedix's debt to equity has shrunk by 50% YoY
CorMedix's equity has decreased by 20% QoQ and by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.